These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 23481700)

  • 21. The HLA Ligandome Comprises a Limited Repertoire of O-GlcNAcylated Antigens Preferentially Associated With HLA-B*07:02.
    Mukherjee S; Sanchez-Bernabeu A; Demmers LC; Wu W; Heck AJR
    Front Immunol; 2021; 12():796584. PubMed ID: 34925382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
    Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
    J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligandomes obtained from different HLA-class II-molecules are homologous for N- and C-terminal residues outside the peptide-binding cleft.
    Kampstra ASB; van Heemst J; Janssen GM; de Ru AH; van Lummel M; van Veelen PA; Toes REM
    Immunogenetics; 2019 Sep; 71(8-9):519-530. PubMed ID: 31520135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
    Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G
    Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.
    Marcilla M; Alpízar A; Lombardía M; Ramos-Fernandez A; Ramos M; Albar JP
    Mol Cell Proteomics; 2014 Feb; 13(2):462-74. PubMed ID: 24366607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naturally processed non-canonical HLA-A*02:01 presented peptides.
    Hassan C; Chabrol E; Jahn L; Kester MG; de Ru AH; Drijfhout JW; Rossjohn J; Falkenburg JH; Heemskerk MH; Gras S; van Veelen PA
    J Biol Chem; 2015 Jan; 290(5):2593-603. PubMed ID: 25505266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The structural basis of HLA-associated drug hypersensitivity syndromes.
    Pompeu YA; Stewart JD; Mallal S; Phillips E; Peters B; Ostrov DA
    Immunol Rev; 2012 Nov; 250(1):158-66. PubMed ID: 23046128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonclassical HLA-G molecules are classical peptide presenters.
    Diehl M; Münz C; Keilholz W; Stevanović S; Holmes N; Loke YW; Rammensee HG
    Curr Biol; 1996 Mar; 6(3):305-14. PubMed ID: 8805247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome.
    Lorente E; Martín-Galiano AJ; Kadosh DM; Barriga A; García-Arriaza J; Mir C; Esteban M; Admon A; López D
    J Proteome Res; 2022 Jan; 21(1):164-171. PubMed ID: 34937342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA class I molecules consistently present internal influenza epitopes.
    Wahl A; Schafer F; Bardet W; Buchli R; Air GM; Hildebrand WH
    Proc Natl Acad Sci U S A; 2009 Jan; 106(2):540-5. PubMed ID: 19122146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
    Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comprehensive analysis of peptides presented by HLA-A1.
    Giam K; Ayala-Perez R; Illing PT; Schittenhelm RB; Croft NP; Purcell AW; Dudek NL
    Tissue Antigens; 2015 Jun; 85(6):492-6. PubMed ID: 25880248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward a definition of self: proteomic evaluation of the class I peptide repertoire.
    Hickman HD; Luis AD; Buchli R; Few SR; Sathiamurthy M; VanGundy RS; Giberson CF; Hildebrand WH
    J Immunol; 2004 Mar; 172(5):2944-52. PubMed ID: 14978097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
    Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
    Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.
    Nijveen H; Kester MG; Hassan C; Viars A; de Ru AH; de Jager M; Falkenburg JH; Leunissen JA; van Veelen PA
    Immunogenetics; 2011 Mar; 63(3):143-53. PubMed ID: 21125265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines.
    Crotzer VL; Christian RE; Brooks JM; Shabanowitz J; Settlage RE; Marto JA; White FM; Rickinson AB; Hunt DF; Engelhard VH
    J Immunol; 2000 Jun; 164(12):6120-9. PubMed ID: 10843661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.
    Hansen BE; Rasmussen AH; Jakobsen BK; Ryder LP; Svejgaard A
    Tissue Antigens; 2007 Jul; 70(1):42-52. PubMed ID: 17559580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What Is the Role of HLA-I on Cancer Derived Extracellular Vesicles? Defining the Challenges in Characterisation and Potential Uses of This Ligandome.
    Boyne C; Lennox D; Beech O; Powis SJ; Kumar P
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
    Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
    Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.